Page 81 - Read Online

Page 10 of 11 Fonseka et al. J Cancer Metastasis Treat 2020;6:7 I http://dx.doi.org/10.20517/2394-4722.2019.024

6. Evans AE, D’Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children’s cancer study group A. Cancer
1971;27:374-8.
7. Cheung NKV, Zhang J, Lu C, Parker M, Bahrami A, et al. Association of age at diagnosis and genetic mutations in patients with
neuroblastoma. JAMA 2012;307:1062-71.
8. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047-53.
9. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, et al. Revisions of the international criteria for neuroblastoma diagnosis,
staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
10. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, et al. Association of Multiple Copies of the N-myc Oncogene with Rapid
Progression of Neuroblastomas. N Engl J Med 1985;313:1111-6.
11. Oppedal BR, Oien O, Jahnsen T, Brandtzaeg P. N-myc amplification in neuroblastomas: histopathological, DNA ploidy, and clinical
variables. J Clin Pathol 1989;42:1148-52.
12. Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, et al. N-Myc gene amplification is a major prognostic factor in localized
neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d’Oncologie Pédiatrique. J Clin
Oncol 1997;15:1171-82.
13. Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, et al. Genetic staging of unresectable or metastatic neuroblastomain infants: a
pediatric oncology group study. J Natl Cancer Inst 1997;89:373-80.
14. Chang PCY, Wang NL, Liu HC, Liang DC, Yeh TC, et al. Low-stage pediatric neuroblastoma: a 20-year single institution review. J
Cancer Res Pract 2018;5:9-12.
15. Sharma R, Mer J, Lion A, Vik TA. Clinical presentation, evaluation, and management of neuroblastoma. Pediatr Rev 2018;39:194-203.
16. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy,
radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73.
17. Luksch R, Castellani MR, Collini P, De Bernardi B, Conte M, et al. Neuroblastoma (Peripheral neuroblastic tumours). Crit Rev Oncol
Hematol 2016;107:163-81.
18. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME, et al. Late mortality experience in five-year survivors of childhood and adolescent
cancer: the childhood cancer survivor study. J Clin Oncol 2001;19:3163-72.
19. Whelan KF, Stratton K, Kawashima T, Waterbor JW, Castleberry RP, et al. Ocular late effects in childhood and adolescent cancer
survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer 2010;54:103-9.
20. Friedman DL, Meadows AT. Late effects of childhood cancer therapy. Pediatr Clin North Am 2002;49:1083-106.
21. Friedman DL, Freyer DR, Levitt GA. Models of care for survivors of childhood cancer. Pediatr Blood Cancer 2006;46:159-68.
22. Nandagopal R, Laverdiere C, Mulrooney D, Hudson MM, Meacham L. Endocrine late effects of childhood cancer therapy: a report from
the Children’s Oncology Group. Horm Res 2008;69:65-74.
23. Dickerman JD. The late effects of childhood cancer therapy. Pediatrics 2007;119:554-68.
24. Rose SR, Horne VE, Howell J, Lawson SA, Rutter MM, et al. Late endocrine effects of childhood cancer. Nat Rev Endocrinol
2016;12:319-36.
25. Perwein T, Lackner H, Sovinz P, Benesch M, Schmidt S, et al. Survival and late effects in children with stage 4 neuroblastoma. Pediatr
Blood Cancer 2011;57:629-35.
26. Son H, Moon A. Epithelial-mesenchymal transition and cell invasion. Toxicol Res 2010;26:245-52.
27. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28:15-33.
28. Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: necessary or permissive for metastasis? Mol Oncol 2017;11:755-69.
29. Yang AD, Fan F, Camp ER, van Buren G, Liu W, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in
colorectal cancer cell lines. Clin Cancer Res 2006;12:4147-53.
30. Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, et al. Establishment and characterization of two 5-fluorouracil-resistant
hepatocellular carcinoma cell lines. Int J Oncol 2012;40:1005-10.
31. Hoshino H, Miyoshi N, Nagai K, Tomimaru Y, Nagano H, et al. Epithelial-mesenchymal transition with expression of SNAI1-induced
chemoresistance in colorectal cancer. Biochem Biophys Res Commun 2009;390:1061-5.
32. Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci 2019;20:1033.
33. Raina K, Kumar S, Dhar D, Agarwal R. Silibinin and colorectal cancer chemoprevention: a comprehensive review on mechanisms and
efficacy. J Biomed Res 2016;30:452-65.
34. Bosch-Barrera J, Queralt B, Menendez JA. Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treat Rev 2017;58:61-9.
35. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006;13:751-78.
36. Sidhar H, Giri RK. Induction of Bex genes by curcumin is associated with apoptosis and activation of p53 in N2a neuroblastoma cells.
Sci Rep 2017;7:41420.
37. Namkaew J, Jaroonwitchawan T, Rujanapun N, Saelee J, Noisa P. Combined effects of curcumin and doxorubicin on cell death and cell
migration of SH-SY5Y human neuroblastoma cells. In Vitro Cell Dev Biol Anim 2018;54:629-39.
38. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang ZS, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat
Biotechnol 2015;33:306-12.
39. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in
deciphering survival and drug responses of cancer patients. EMBO Mol Med 2014;6:1279-93.
40. Mathivanan S, Ji H, Tauro BJ, Chen YS, Simpson RJ. Identifying mutated proteins secreted by colon cancer cell lines using mass
spectrometry. J Proteomics 2012;76:141-9.